Lixte Biotechnology Chief Financial Officer Robert N. Weingarten Resigns
Lixte Biotechnology Holdings disclosed the resignation of CFO Robert N. Weingarten effective May 29, 2026. The departure triggers standard SEC reporting obligations and requires the company to identify a replacement or interim officer to maintain Exchange Act compliance.
manilatimes.netLixte Biotechnology Holdings Inc. (NASDAQ: LIXT) reported the resignation of its chief financial officer, Robert N. Weingarten, according to an 8-K filed with the SEC on June 1, 2026.
The filing, submitted under Items 5.02, 7.01 and 9.01, states that Weingarten resigned from his position as principal financial and accounting officer effective May 29, 2026. The company did not disclose a reason for the departure or name an immediate successor.
Lixte is a clinical-stage biotechnology company developing phosphatase inhibitor drug candidates. Weingarten had served as CFO since 2012 and signed the company’s most recent quarterly and annual reports. His exit leaves the small-cap issuer without a permanent principal financial officer.
The change takes effect immediately. Under SEC rules, Lixte must file any subsequent Form 8-K if it appoints a new principal financial officer or elects an interim officer to assume signing authority for future Exchange Act filings. Until a replacement is named, the company’s chief executive officer or another authorized officer will likely assume temporary responsibility for financial disclosures.
Downstream, the resignation starts the clock on Lixte’s obligation to update investors through a Regulation FD-compliant disclosure, which the filing itself satisfies. It also creates an immediate operational gap in financial reporting, internal control oversight and audit committee communications that must be addressed before the company’s next required quarterly report on Form 10-Q.
Failure to maintain a qualified principal financial officer could delay SEC filings and trigger Nasdaq listing-rule inquiries.
This marks the second executive-level departure Lixte has reported in the past 24 months. The company’s prior 8-K filings show it has relied on part-time or consulting finance executives consistent with its micro-cap biotech profile. The current 8-K includes an exhibit with the full resignation letter.
Primary sources: SEC Form 8-K filed June 1, 2026 (Accession No. 0001493152-26-026544).
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Related Stories
asiaone.comIranian Official: Tehran Manages Strait of Hormuz and Will Not Allow Maritime Blockade
Mohsen Rezaei stated that Iran controls the Strait of Hormuz and will not allow a maritime blockade to continue. Oil prices rose 8 percent on the day of the statements.
Substrate placeholder — needs reviewIran Suspends Indirect Talks With U.S. Amid Escalating Israel-Hezbollah Conflict in Lebanon
Iran has stopped all message exchange with the United States, including ongoing talks, in response to Israel's expanded offensive in Lebanon. The suspension was reported by Tasnim News Agency, which is affiliated with the Islamic Revolutionary Guard Corps according to the Jerusal…
Al JazeeraGreece Reviews Asylum Status for Syrians and Afghans After Conflicts End
Greek authorities began reviewing protection status for Syrians and Afghans in February after the end of Syria's civil war and the 2021 Taliban takeover. The reviews target men and coincide with new returns legislation.